MedicQuant at INCUBA raises DKK 22M to advance technology for acute stroke treatment
MedicQuant is a spinout from Aarhus University and builds on more than 11 years of research in DNA nanotechnology. Since 2023, the company has been based at INCUBA, where it has developed from a research project into a growing company.
The company is developing a point-of-care test platform capable of measuring levels of anticoagulants in patients suspected of stroke. The goal is to provide clinicians with faster answers in one of the most time-critical areas of healthcare, where every minute can be decisive for survival and long-term outcomes.
“The first time a stroke patient receives faster treatment because our device helped clinicians get an earlier answer will mean everything. That is the future we are working towards,” says Line Debois, CEO and co-founder of MedicQuant.
With the new investment, MedicQuant now enters its next phase, focusing on completing product development, advancing clinical studies and preparing for market entry.
From research to business at INCUBA
MedicQuant is part of INCUBA, where the company has developed in close collaboration with other companies, investors and research environments.
“Being part of INCUBA has been highly valuable for us. We have had the opportunity to establish our own laboratories, scale our team and spar with other companies facing many of the same challenges. At the same time, we have become part of a strong environment with excellent facilities in our daily work,” says Malthe Hansen-Bruhn, CTO and co-founder of MedicQuant.
At INCUBA, the investment is seen as another strong example of how research-based companies can grow and attract capital.
“MedicQuant is an excellent example of how research can be translated into a business with global potential. At INCUBA, we work actively to create the best possible conditions for companies to develop, scale and attract investment. This requires facilities, strong professional environments and close interaction between companies and investors,” says Jacob Doktor Mogensen, CEO of INCUBA.
He adds:
“It is a pleasure to follow MedicQuant’s journey and to see such a strong case succeed. Congratulations to both the team and Delphinus Venture Capital on the investment.”
With this investment, MedicQuant is now better positioned to bring its technology closer to clinical application and contribute to improved treatment for patients worldwide.
